Rare diseases are finally getting their due in the US Food and Drug Administration’s advisory committee system.
On 12 December, the FDA announced the establishment of a new expert panel – the Genetic Metabolic Diseases Advisory Committee (GeMDAC) – to provide independent advice and recommendations on technical, scientific and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?